Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company's subsidiary, Beijing Shengdi Pharmaceutical Co., Ltd. received approval from the State Drug Administration to issue a “Pharmaceutical Clinical Trial Approval Notice” for SHR-3201 injection and will conduct clinical trials in the near future. Indications for application: Alzheimer's disease.

Zhitongcaijing · 3d ago
Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company's subsidiary, Beijing Shengdi Pharmaceutical Co., Ltd. received approval from the State Drug Administration to issue a “Pharmaceutical Clinical Trial Approval Notice” for SHR-3201 injection and will conduct clinical trials in the near future. Indications for application: Alzheimer's disease.